Sustained complete response to TMEp-CI-M platform in refractory small-cell lung cancer with brainstem metastasis: a case report with over 20 months of disease-free survival - Summary - MDSpire

Sustained complete response to TMEp-CI-M platform in refractory small-cell lung cancer with brainstem metastasis: a case report with over 20 months of disease-free survival

  • By

  • Yating Wu

  • Hang Li

  • Yonghai Peng

  • Weiqiang Fan

  • June 1, 2026

  • 0 min

Share

Objective:

To report a case of brainstem metastasis from small-cell lung cancer (SCLC) treated with the TMEp-CI-M platform, achieving no evidence of disease for over 20 months.

Key Findings:
  • The patient achieved normalization of pro-gastrin-releasing peptide (ProGRP) levels after the first treatment cycle.
  • The patient remained disease-free for over 20 months post-treatment.
  • Only Grade 1 hypothyroidism was reported as an adverse event.
Interpretation:

Limitations:
  • This is a single case study, limiting generalizability.
  • Further prospective and mechanistic studies are needed to confirm clinical utility.
Conclusion:

Original Source(s)

Sustained complete response to TMEp-CI-M platform in refractory small-cell lung cancer with brainstem metastasis: a case report with over 20 months of disease-free survival

  • by Yating Wu, Hang Li, Yonghai Peng, Weiqiang Fan

  • June 1, 2026

Related Content

High-grade astrocytoma with piloid features: a case report of comprehensive management

VANGL1 links angiogenesis–stemness programs and tumor microenvironment remodeling: a pan-cancer, multi-omics study with translational validation

Four-dimensional computed tomography ventilation imaging-guided radiotherapy planning in different techniques for lung cancer